Platzbecker, U <br/><br/>
Lenalidomide as induction therapy before allogeneic stem cell transplantation in a patient with proliferative CMML-2 and del(5q) not involving the EGR1 locus.  [electronic resource] 

 -  Leukemia  Nov 2007 
 - 2384-5 p.  digital 
<br/><br/> Publication Type: Letter 
<br/><br/><label>ISSN: </label>0887-6924 
<br/><br/><label>Standard No.: </label>10.1038/sj.leu.2404811  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Agents--therapeutic use<br/>Cell Proliferation<br/>Chromosomes, Human, Pair 5<br/>Cytogenetics<br/>Early Growth Response Protein 1--genetics<br/>Gene Deletion<br/>Humans<br/>Lenalidomide<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--genetics<br/>Male<br/>Remission Induction<br/>Stem Cell Transplantation--methods<br/>Thalidomide--analogs & derivatives<br/>Time Factors<br/>Transplantation, Homologous--methods